Alnylam ( Alnylam)

Primary tabs

Alnylam's picture

Management

Contact Address

About Alnylam

Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

Alnylam press release, blog etc

Fri, 03/28/2025 - 17:35 FDA Approves Qfitlia (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Wed, 03/05/2025 - 07:02 Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
Wed, 08/07/2024 - 13:27 Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
Wed, 12/21/2022 - 06:11 Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Thu, 12/15/2022 - 04:55 Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
Wed, 12/07/2022 - 19:25 Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Thu, 12/01/2022 - 06:52 Alnylam Ranks #1 on Boston Globes Top Places to Work List for 2022
Thu, 10/27/2022 - 14:46 Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
Wed, 09/21/2022 - 04:08 Alnylam Announces New Management Appointments
Tue, 09/20/2022 - 06:07 Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Mon, 09/19/2022 - 09:55 Alnylam to Host Ninth Annual RNAi Roundtable Webcast Series
Tue, 09/13/2022 - 09:41 Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
Mon, 09/12/2022 - 02:13 Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
Mon, 08/29/2022 - 18:47 Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Wed, 08/24/2022 - 14:21 Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
Thu, 08/18/2022 - 04:50 Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
Tue, 08/02/2022 - 09:39 Alnylam Ranks #1 on Fast Companys Fourth Annual List of the 100 Best Workplaces for Innovators
Wed, 07/27/2022 - 06:49 Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
more

InfoBox

HomePagewww.alnylam.com
Twittertwitter.com/Alnylam
YouTubewww.youtube.com/channel/UCUZReY0GSAJ1w-MULQb9_Rw
LinkedInwww.linkedin.com/company/alnylam-pharmaceuticals
Wikipediaen.wikipedia.org/wiki/Alnylam_Pharmaceuticals